LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

Начало・Списък с акции・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

97.69 -2.15

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

95.71

Максимум

100.96

Ключови измерители
By Trading Economics
Приходи	2.9M -47M
Продажби	16M 49M
Марж на печалбата	-96.144
Служители	283
EBITDA	6.9M -40M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+25.18% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.6B 7.6B
Предишно отваряне	99.84
Предишно затваряне	97.69

Настроения в новините

By Acuity

48%

52%

157 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

60 / 65.58 Подкрепа & съпротива

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.11.2025 г., 21:36 ч. UTC

Печалби

Australia's ANZ Bank Posts 10% Drop in Annual Profit -- Update

9.11.2025 г., 21:22 ч. UTC

Печалби

Australia's ANZ Bank Posts 10% Drop in Annual Profit

10.11.2025 г., 00:00 ч. UTC

Пазарно говорене

India Inflation Poised to Hit New Low -- Market Talk

9.11.2025 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise on Weaker Yen, Earnings Hopes -- Market Talk

9.11.2025 г., 23:35 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Signs of U.S. Economic Weakness -- Market Talk

9.11.2025 г., 21:05 ч. UTC

Печалби

ANZ FY Total Operating Expenses A$12.88B Vs. A$11.465B Pro Forma>ANZ.AU

9.11.2025 г., 21:04 ч. UTC

Печалби

ANZ FY Operating Expenses A$11.85B Ex-Significant Items>ANZ.AU

9.11.2025 г., 21:03 ч. UTC

Печалби

ANZ 2H Net Interest Margin 1.54% Vs. 1.56% in 1H>ANZ.AU

9.11.2025 г., 20:49 ч. UTC

Печалби

ANZ FY Australia Retail Deposits Up 6% on Year>ANZ.AU

9.11.2025 г., 20:49 ч. UTC

Печалби

ANZ FY Australia Home Loan Lending Up 5% on Year>ANZ.AU

9.11.2025 г., 20:45 ч. UTC

Печалби

ANZ FY Average Customer Deposits A$760.8B Vs. A$669.4B>ANZ.AU

9.11.2025 г., 20:45 ч. UTC

Печалби

ANZ FY Average Gross Loans & Advances A$833.6B Vs. A$733.8B>ANZ.AU

9.11.2025 г., 20:42 ч. UTC

Печалби

ANZ FY Results Include Full-Year Benefit of Suncorp Bank Acquisition>ANZ.AU

9.11.2025 г., 20:42 ч. UTC

Печалби

ANZ FY Net Interest Margin 1.55% Vs. 1.57%>ANZ.AU

9.11.2025 г., 20:41 ч. UTC

Печалби

ANZ FY Common Equity Tier 1 Ratio 12.0% Vs. 12.2%>ANZ.AU

9.11.2025 г., 20:41 ч. UTC

Печалби

ANZ FY Net Profit Includes A$1.11B of Notable Items>ANZ.AU

9.11.2025 г., 20:39 ч. UTC

Печалби

ANZ FY Credit Impairment Charge A$441M Vs. A$406M>ANZ.AU

9.11.2025 г., 20:39 ч. UTC

Печалби

ANZ FY Rev A$22.19B Vs. A$20.55B >ANZ.AU

9.11.2025 г., 20:38 ч. UTC

Печалби

ANZ Keeps Dividend at A$0.83 >ANZ.AU

9.11.2025 г., 20:38 ч. UTC

Печалби

ANZ FY Cash Profit A$5.79B Vs. A$6.725B>ANZ.AU

9.11.2025 г., 20:38 ч. UTC

Печалби

ANZ FY Net A$5.89B Vs. Net A$6.535B >ANZ.AU

8.11.2025 г., 13:10 ч. UTC

Придобивния, сливания и поглъщания

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- Update

8.11.2025 г., 03:50 ч. UTC

Придобивния, сливания и поглъщания

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- 4th Update

8.11.2025 г., 03:41 ч. UTC

Придобивния, сливания и поглъщания

Pfizer and Metsera Reach Deal Expected to Top $10 Billion -- WSJ

8.11.2025 г., 03:07 ч. UTC

Придобивния, сливания и поглъщания

Pfizer and Metsera Reach Deal Worth Up to $10 Billion -- WSJ

7.11.2025 г., 22:36 ч. UTC

Печалби

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7.11.2025 г., 22:22 ч. UTC

Печалби

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7.11.2025 г., 22:03 ч. UTC

Печалби

Constellation Software 3Q Rev $2.95B >CSU.T

7.11.2025 г., 22:03 ч. UTC

Печалби

Constellation Software 3Q Net $210M >CSU.T

7.11.2025 г., 22:03 ч. UTC

Печалби

Constellation Software 3Q EPS $9.89 >CSU.T

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

25.18% нагоре

12-месечна прогноза

Среден 125.56 USD 25.18%

Висок 142 USD

Нисък 110 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

157 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.